Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome.
about
Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients.Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trialsA Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.Trends in endpoint selection in clinical trials of advanced breast cancer.
P2860
Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Overall survival (OS) endpoint ...... ancer (MBC) treatment outcome.
@en
type
label
Overall survival (OS) endpoint ...... ancer (MBC) treatment outcome.
@en
prefLabel
Overall survival (OS) endpoint ...... ancer (MBC) treatment outcome.
@en
P2860
P1476
Overall survival (OS) endpoint ...... ancer (MBC) treatment outcome.
@en
P2093
Jacques Raphael
P2860
P2888
P304
P356
10.1007/S10549-015-3342-2
P407
P577
2015-03-19T00:00:00Z
P6179
1029315116